267 related articles for article (PubMed ID: 9293041)
21. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits.
Parrott AC; Lees A; Garnham NJ; Jones M; Wesnes K
J Psychopharmacol; 1998; 12(1):79-83. PubMed ID: 9584971
[TBL] [Abstract][Full Text] [Related]
22. Syllogistic reasoning performance in MDMA (Ecstasy) users.
Montgomery C; Fisk JE; Newcombe R; Wareing M; Murphy PN
Exp Clin Psychopharmacol; 2005 May; 13(2):137-45. PubMed ID: 15943546
[TBL] [Abstract][Full Text] [Related]
23. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
Morgan MJ; McFie L; Fleetwood H; Robinson JA
Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
[TBL] [Abstract][Full Text] [Related]
24. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.
Lamers CT; Bechara A; Rizzo M; Ramaekers JG
J Psychopharmacol; 2006 Mar; 20(2):302-11. PubMed ID: 16510488
[TBL] [Abstract][Full Text] [Related]
25. Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users.
Parrott AC; Rodgers J; Buchanan T; Ling J; Heffernan T; Scholey AB
Hum Psychopharmacol; 2006 Jul; 21(5):285-98. PubMed ID: 16856221
[TBL] [Abstract][Full Text] [Related]
26. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
[TBL] [Abstract][Full Text] [Related]
27. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
28. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
[TBL] [Abstract][Full Text] [Related]
29. MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task.
Vollenweider FX; Liechti ME; Paulus MP
J Psychopharmacol; 2005 Jul; 19(4):366-74. PubMed ID: 15982991
[TBL] [Abstract][Full Text] [Related]
30. Executive function in abstinent MDMA ('ecstasy') users.
Zakzanis KK; Young DA
Med Sci Monit; 2001; 7(6):1292-8. PubMed ID: 11687745
[TBL] [Abstract][Full Text] [Related]
31. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.
Parrott AC
J Psychopharmacol; 2005 Jan; 19(1):71-83. PubMed ID: 15671132
[TBL] [Abstract][Full Text] [Related]
32. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
[TBL] [Abstract][Full Text] [Related]
33. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
34. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users.
Gouzoulis-Mayfrank E; Thimm B; Rezk M; Hensen G; Daumann J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):819-27. PubMed ID: 12921915
[TBL] [Abstract][Full Text] [Related]
35. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
Gouzoulis-Mayfrank E; Daumann J
J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
[TBL] [Abstract][Full Text] [Related]
36. No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study.
Gamma A; Buck A; Berthold T; Vollenweider FX
J Clin Psychopharmacol; 2001 Feb; 21(1):66-71. PubMed ID: 11199950
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
Hanson KL; Luciana M
J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
[TBL] [Abstract][Full Text] [Related]
38. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use.
Butler GK; Montgomery AM
Drug Alcohol Depend; 2004 Oct; 76(1):55-62. PubMed ID: 15380289
[TBL] [Abstract][Full Text] [Related]
39. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA.
Hasler F; Studerus E; Lindner K; Ludewig S; Vollenweider FX
J Psychopharmacol; 2009 Nov; 23(8):923-35. PubMed ID: 18635693
[TBL] [Abstract][Full Text] [Related]
40. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
Medina KL; Shear PK; Corcoran K
J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
